Rare disease focus Jaguar Health is actively pursuing NDA filings for crofelemer to treat microvillus inclusion disease and other pediatric intestinal failure conditions, indicating a strong opportunity to position specialized clinical trial support, CRO partnerships, and payer engagement services around ultra-rare indications.

Clinical trial expansion All randomized pediatric patients have entered a single-blind extension phase to support longer-term safety and efficacy data, signaling demand for near-term trial management, data analytics, and patient recruitment partnerships to sustain and accelerate pivotal studies.

New product lines Launch of Neonorm Dog expands the consumer health portfolio into pet GI support with a plant-based, non-prescription product, presenting upsell opportunities for e-commerce enablement, pet care marketing automation, and channel partnerships with retailers like Amazon and Chewy.

Commercial readiness Expected NDA readiness by end of 2026 and mid-2027 FDA submission timeline indicate a need for commercialization planning services, including market access strategy, physician and patient advocacy engagement, and regulatory affairs support.

Financial visibility Reported revenue range of 10 to 25 million alongside ongoing investor communications and earnings webcasts suggests opportunity to offer investor relations services, financial modeling, and scalable marketing analytics to support corporate communications and growth storytelling.